Bioventus
BVS
66 hedge funds and large institutions have $92.6M invested in Bioventus in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 32 reducing their positions, and 20 closing their positions.
925% more call options, than puts
Call options by funds: $738K | Put options by funds: $72K
176% more capital invested
Capital invested by funds: $33.6M → $92.6M (+$59.1M)
0.74% more ownership
Funds ownership: 50.46% → 51.2% (+0.74%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 71 → 66 (-5)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
59% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JIC
Juniper Investment Company
New York
|
+$3.96M |
| 2 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
+$1.77M |
| 3 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$985K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$852K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$781K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.83M |
| 2 |
Millennium Management
New York
|
-$1.55M |
| 3 |
State Street
Boston,
Massachusetts
|
-$826K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$568K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$392K |
BVS Hedge Fund Activity: Q2 2023 in Review
66 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q2 2023, worth a combined $92.6M — up 176% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of BVS and 15 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 13 added.
The largest buyer was Juniper Investment Company, adding an estimated $3.96M. The largest seller was BlackRock, cutting an estimated $2.83M.
- 66 institutional investors held Bioventus (BVS) as of Q2 2023, down from 71 in Q1 2023.
- Funds reported $92.6M of Bioventus stock for Q2 2023, up 176% quarter-over-quarter.
- 15 funds opened new Bioventus positions in Q2 2023 and 20 closed out, a net change of -5 holders.
- The largest Bioventus buyer in Q2 2023 was Juniper Investment Company, an estimated $3.96M added.
- The largest Bioventus seller in Q2 2023 was BlackRock, an estimated $2.83M sold.
Based on aggregated 13F filings for Q2 2023.